PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-4.62%
Both companies reducing G&A. Martin Whitman would check industry cost trends.
No Data
No Data available this quarter, please select a different quarter.
8.49%
Other expenses change of 8.49% while RVPH maintains costs. Bruce Berkowitz would investigate efficiency.
-3.29%
Both companies reducing operating expenses. Martin Whitman would check industry trends.
-3.29%
Both companies reducing total costs. Martin Whitman would check industry trends.
-91.94%
Both companies reducing interest expense. Martin Whitman would check industry trends.
No Data
No Data available this quarter, please select a different quarter.
3.29%
EBITDA growth 50-75% of RVPH's 5.85%. Martin Whitman would scrutinize operations.
No Data
No Data available this quarter, please select a different quarter.
3.29%
Operating income growth below 50% of RVPH's 7.11%. Michael Burry would check for structural issues.
No Data
No Data available this quarter, please select a different quarter.
-3.29%
Both companies reducing other expenses. Martin Whitman would check industry patterns.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-27.01%
Tax expense reduction while RVPH shows 52.58% growth. Joel Greenblatt would examine advantage.
27.01%
Net income growth exceeding 1.5x RVPH's 5.90%. David Dodd would verify competitive advantages.
No Data
No Data available this quarter, please select a different quarter.
26.90%
EPS growth exceeding 1.5x RVPH's 7.69%. David Dodd would verify competitive advantages.
26.90%
Diluted EPS growth exceeding 1.5x RVPH's 7.69%. David Dodd would verify competitive advantages.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.